芪苈强心胶囊对扩张型心肌病患者心功能及高迁移率族蛋白B1表达的影响

Influences of Qili Qiangxin Capsules on heart function and expression of high mobility group box 1 protein(HMGB1) in patients with dilated cardiomyopathy

目的观察芪苈强心胶囊对扩张型心肌病患者心功能及高迁移率族蛋白B1(HMGB1)表达的影响。方法连续入选2012年1月～2013年8月在宜昌市中心人民医院心内科住院心功能(NYHA分级)Ⅱ～Ⅲ级的扩张型心肌病患者48例,随机分为观察组和对照组(各24例),两组患者均给予规范的西药治疗,观察组在此基础上加用芪苈强心胶囊(0.3 g/粒),每次4粒,3/日,疗程12周。分别测量两组患者治疗前后的6分钟步行距离(6MWT)及左室射血分数(LVEF);采用ELISA法检测两组患者血清中HMGB1、白细胞介素6(IL-6)及肿瘤坏死因子-α(TNF-α)的表达水平。结果与治疗前比较,治疗后两组患者6MWT、LVEF均显著提高(P<0.01),血清中HMGB1、IL-6及TNF-α的表达水平明显降低(P<0.01)。对照组治疗后6MWT为(365±59)m,LVEF为(39.3±8.8)%,与对照组比较,观察组治疗后6MWT[(389±63)m]、LVEF[(44.6±9.3)%]显著升高(P<0.05)。对照组治疗后,血清中HMGB1、IL-6及TNF-α的水平分别为(13.37±3.86)pg/ml,(89.1±18.5)ng/ml,(18.3±4.2)ng/ml。与对照组治疗后比较,观察组治疗后血清中HMGB1[(9.61±3.25)pg/ml]、IL-6[(65.9±12.4)ng/ml]及TNF-α[(13.6±3.5)ng/ml]的表达水平降低(P<0.05)。结论芪苈强心胶囊辅助治疗能进一步改善扩张型心肌病患者的心功能,同时降低HMGB1及IL-6、TNF-α的表达。

Objective To observe the influences of Qili Qiangxin Capsules on heart function and expression of high mobility group box 1 protein （HMGB1） in the patients with dilated cardiomyopathy （DCM）. Methods The patients （n=48） with grade II DCM and grade III DCM （NYHAgrading） were chosen from Jan. 2012 to Aug. 2013, and then divided randomly into observation group and control group （each n=24）. Both groups were given standardized therapy of Western drugs and observation group was additionally given Qili Qiangxin Capsules （0.3 g/capsule） 4 capsules once and 3 times a day for 12 w. The changes of 6-minute walk test （6MWT） and LVEF were detected in 2 groups before and after treatment. The expressions of serum HMGB1, IL-6 and TNF-αwere detected by using ELISA. Results 6MWT and LVEF were increased significantly （P〈0.01）, and expressions of serum HMGB1, IL-6 and TNF-αdecreased significantly （P〈0.01） in 2 groups after treatment. 6MWT was （365 ±59） m and LVEF was （39.3±8.8）%in control group, and 6MWT was [（389±63） m] and LVEF was [（44.6± 9.3）%] in observation group after treatment （P〈0.05）. The expressions of serum HMGB1, IL-6 and TNF-αwere, respectively, （13.37±3.86） pg/ml, （89.1±18.5） ng/ml and （18.3±4.2） ng/ml in control group, and[（9.61±3.25） pg/ml], [（65.9±12.4） ng/ml] and [（13.6±3.5） ng/ml] in observation group after treatment （P〈0.05）. Conclusion Qili Qiangxin Capsules can further improve heart function and reduce the expressions of HMGB1, IL-6 and TNF-αduring treatment in the patients with DCM.